MedStar Authors catalog › Details for: Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. [Review]
Normal view MARC view ISBD view

Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. [Review]

by Ylli, Dorina; Van Nostrand, Douglas; Wartofsky, Leonard.
Citation: Endocrinology & Metabolism Clinics of North America. 48(1):181-197, 2019 03..Journal: Endocrinology and metabolism clinics of North America.Published: ; 2019ISSN: 0889-8529.Full author list: Ylli D; Van Nostrand D; Wartofsky L.UI/PMID: 30717901.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment(s): Medicine/Nuclear Medicine | Medicine/EndocrinologyActivity type: Journal Article.Medline article type(s): Journal Article | ReviewDigital Object Identifier: https://dx.doi.org/10.1016/j.ecl.2018.11.005 (Click here) Abbreviated citation: Endocrinol Metab Clin North Am. 48(1):181-197, 2019 03.Local Holdings: Available online from MWHC library: 1996 - present.Abstract: This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients with differentiated thyroid cancer. Topics reviewed include definitions; staging; the 2 principal methods for selection of 131-I dosage; the indications for ablation, adjuvant treatment, and treatment; the recommendations for the use of 131-I contained in the guidelines of the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging; the dosage recommendations and selection of dosage approach for 131-I by these organizations; the use of recombinant human thyrotropin for radioiodine ablation, adjuvant therapy, or treatment; and the MedStar Washington Hospital Center approach.Abstract: Copyright (c) 2018 Elsevier Inc. All rights reserved.

Powered by Koha